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ABSTRACT
Background: Coenzyme Q10 is a well-known cofactor in the mitochondrial electron transport chain required for ATP produc-
tion. Coenzyme Q10 is recognized as an intracellular antioxidant that protects cell membrane phospholipids, mitochondrial 
membrane protein, and plasma low-density lipoprotein against oxidative damage caused by free radicals. Diabetes and 
its complications have been related to increased levels of free radicals and systemic proinflammatory cytokines and to 
an abnormal lipid profile. The aim of this study was to investigate the effects of coenzyme Q10 supplementation on some 
cytokine levels in streptozotocin-induced diabetic rats.
Materials, Methods & Results: In this study, 38 healthy, adult male rats were used. The rats were divided into 5 groups. 
All animals were housed in separated cages during the four weeks. The animals in group 1 was fed standard rat pellets for 
4 weeks. It was administered at 0.3 mL corn oil intraperitoneally daily for four weeks in group 2 animals. The animals in 
group 3 was injected intraperitoneally with 10 mg/kg CoQ10 daily for 4 weeks. Group 4 was made diabetic by subcutaneous 
injections of streptozotocin at dose of 40 mg/kg in 0.1 M citrate buffer (pH 4.5) single daily dose for two days and group 5 
was made diabetic by subcutaneous injections of streptozotocin at dose of 40 mg/kg in 0.1 M citrate buffer (pH 4.5) single 
daily dose for two days and then was injected intraperitoneally with 10 mg/kg CoQ10 daily for 4 weeks. During the experi-
ment, three animals from group 4 and one animals from group 5 were died due to streptozotocin-induced hypoglycemia. 
At the end of the study, blood samples were taken from all animals. In these blood samples, IL-4, IL-6, IL-10 and TNF-α 
plasma levels were determined with ELISA using sandwich enzyme-linked immunosorbent method via commercial kits. In 
this study, IL-4 level as an anti-inflammatory cytokine significantly decreased (P < 0.05) with diabetes induction compared 
to control group level. IL-10 level in diabetic group was statistically different (P < 0.05) from control group level. CoQ10 
application to diabetic animals improved the falling in IL-10 level of diabetic group (P < 0.05). IL-6 and TNF-α levels in 
diabetic group significantly increased (P < 0.05) in parallel with each other compared to control group levels. The same 
parameters were reduced (P < 0.05) by CoQ10 application in diabetic animals.  
Discussion: In this study, the occurred changes in pro- and anti-inflammatory cytokines with experimentally induced diabetes 
are expected results and these results are consistent with some studies related diabetes. These results may be considered 
to hazardous effects and inflammation caused by diabetes on liver, pancreas and other tissues. CoQ10 suppressed the incre-
ments in plasma pro-inflammatory cytokine levels, whereas it restored the reducing in anti-inflammatory cytokine levels 
arising due to diabetes. The obtained results from this study after CoQ10 application supported similar studies used CoQ10 
application against deleterious effects of diabetes in animals and humans. Therefore, it is possible to say that CoQ10 may 
play important role in regulation of imbalance between inflammation markers in diabetes conditions and further studies 
are needed to clear the beneficial effects of CoQ10 treatment on the other inflammation markers in diabetes status. 
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INTRODUCTION
Type 1 diabetes is an autoimmune disease and 
characterized with islet β-cells destroying by a response 
mediated by T lymphocytes that react specifically to 
one or more β-cell proteins [3]. Type 1 diabetes also 
is accepted as a Th1-mediated disease and CD4- and 
CD8-positive T lymphocytes secreting IFN-γ are re-
sponsible for β-cell destruction, thus favoring cellular 
immunity [22]. However, Th1 activities are downregu-
lated by Th2 cells secreting IL-4 and IL-10. In type 
1 diabetes conducted animal models, it was reported 
that increments in Th2 activities prevented autoim-
mune responses augmented by Th1 cells in diabetes 
[14,20,23,29]. Rabinovitch [21] reported that cytokines 
as regulators and mediators of immune responses might 
have important roles in the pathogenesis of IDDM. 
Coenzyme Q10 (CoQ10) is required for ATP pro-
duction in the mitochondrial electron transport chain 
as a well-known cofactor. CoQ10 which is known ubi-
quinone or ubidecarenone is synthesized endogenously 
in organisms and can also be received from exogenous 
food sources [27]. In addition to its important role in 
cell energy metabolism, the ubiquinol form of CoQ10 
has potent lipophilic antioxidant effects. This func-
tion was accomplished either directly via protecting 
cellular components from free radicals or indirectly 
through regeneration of other endogenous antioxidants 
[4,5]. In experimental studies, it has been demonstrated 
antioxidant, anti-inflammatory and ATP-regenerative 
properties of CoQ10 in various diseases such as gastric 
ulcer, osteoarthritis and diabetes [6,7,15,16]. 
The study was conducted to determine the 
effects of coenzyme Q10 on inflammation markers in 
streptozotocin-induced diabetic rats.
MATERIALS AND METHODS
In this study, 38 healthy, adult male Wistar 
Albino rats were used. The animals were housed in 
separated cages during the four weeks experiment 
and allowed free access to water and standard pellets. 
Diabetes was induced by subcutaneous injection of 
streptozotocin1 at a dose of 40 mg/kg daily in 0.1 M 
citrate buffer (pH 4.5) single daily dose for 2 days. 
To prevent the streptozotocin-induced hypoglyce-
mia, rats received 5% dextrose solution after 6 h of 
streptozotocin administration for next 3 days. After 1 
week, induction of diabetes was verified by measur-
ing blood glucose level with strips using glucometer 
(PlusMED Accuro)2 via the tail vein. Animals having 
a blood glucose level higher than 250 mg/dL were 
considered diabetic and included in the experiments. 
The mean weights of all groups were similar. The rats 
were divided into 5 groups. The animals in group 1 (n 
= 6) were fed standard rat pellets for 4 weeks. It was 
administered at 0.3 mL corn oil intraperitoneally daily 
for 4 weeks in group 2 (n = 6) animals. The animals 
in group 3 (n = 6) was injected intraperitoneally with 
10 mg/kg CoQ10 (Coenzyme Q10)1 daily for 4 weeks. 
Group 4 (n = 7) was made diabetic by subcutaneous 
injections of streptozotocin at dose of 40 mg/kg in 0.1 
M citrate buffer (pH 4.5) single daily dose for two days 
and group 5 (n = 9) was made diabetic by subcutaneous 
injections of streptozotocin in the same way and then 
was injected intraperitoneally with 10 mg/kg CoQ10 
daily for 4 weeks. During the experiment, three animals 
from group 4 and one animals from group 5 were died 
due to streptozotocin-induced hypoglycemia.
At the end of the study, blood samples were 
taken from all animals. In these blood samples, IL-4, 
IL-6, IL-10 and TNF-α plasma levels were deter-
mined with ELISA (Biotek ELx800)3 using sandwich 
enzyme-linked immunosorbent method via commercial 
kits (Cytokine kits)4.  
The data were analyzed using one-way ANO-
VA (SPSS 17). Differences among the groups were 
determined by Duncan’s multiple range test. Differ-
ences were considered significant at P < 0.05. 
RESULTS
In this study, IL-4 level as an anti-inflammatory 
cytokine significantly decreased (P < 0.05 ; Table 1) 
with diabetes induction compared to control group 
level. Although IL-4 level in diabetic group treated 
with CoQ10 was found to be higher than diabetic group, 
this change was not important. IL-10 level in diabetic 
group was statistically different (P < 0.05 ; Table 1) 
from control group level. CoQ10 application to diabetic 
animals improved the falling in IL-10 level of diabetic 
group (P < 0.05 ; Table 1). IL-6 and TNF-α levels in 
diabetic group significantly increased (P < 0.05 ; Table 
1) in parallel with each other compared to control group 
level. The same parameters were reduced (P < 0.05 
; Table 1) by CoQ10 application in diabetic animals. 
There are no differences among control, oil and CoQ10 
groups regarding to IL-4, IL-6, IL-10 and TNF-α levels.
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Group 1 8.98 ± 1.19a 55.73 ± 4.81c 51.58 ± 3.65a 96.28 ± 4.03c
Group 2 8.52 ± 0.96a 53.52 ± 5.63c 50.53 ± 3.32a 93.67 ± 4.21c
Group 3 9.13 ± 0.63a 50.78 ± 4.31c 53.35 ± 5.22a 98.57 ± 5.76c
Group 4 5.89 ± 0.57b 81.87 ± 2.48a 28.36 ± 3.65c 143.59 ± 7.63a
Group 5 7.52 ± 0.80ab 68.93 ± 2.27b 39.61 ± 2.58b 123.43 ± 4.48b
The difference between mean values with different superscripts in the same column is significant at the P < 0.05 level. Group 
1. control; group 2. oil; group 3. CoQ10; group 4. diabetes; group 5. CoQ10 and diabetes.
DISCUSSION
Hyperglycemia and hyperlipidemia in diabetes 
are associated with diminished antioxidant enzymes 
production and increased formation of reactive oxygen 
species (ROS) [19]. Excessive ROS provokes inflam-
mation and developed pancreatitis triggers systemic 
inflammatory response via release of mediators from 
immune cells [1,18,25]. In consistence with above 
acknowledgement, we have found the increase in 
pro-inflammatory cytokines with diabetes compared 
to control group in our study (P < 0.05 ; Table 1). In 
our study, the important increases in IL-6 and TNF-α 
levels with diabetes supported the data noted by Rabi-
novitch [21]. 
Several studies reported that anti-inflammatory 
cytokines (IL-4 and IL-10) have been founded to be 
decreased or unchanged [2,11,14,21]. In the experi-
ment, IL-4 and IL-10 levels significantly decreased 
(P < 0.05 ; Table 1) in diabetic rats when compared to 
control group. This result supported the previous re-
ports about the same cytokines obtained from diabetic 
rats. In diabetic rats IL-10 level showed the significant 
decrease [2]. Saxena et al. [26] have considered dia-
betes as a metabolic pro-inflammatory disorder that 
affected highly levels of circulating cytokines via 
severe hyperglycemia. 
In the present study, CoQ10 injection for four 
weeks to the diabetic animals resulted significantly 
decreases (P < 0.05 ; Table 1) IL-6 and TNF-α levels 
compared to diabetic group animals. Our findings are 
agreement with many studies. CoQ10 significantly at-
tenuated TNF-α level in ulcerative colitis in rats [7]. 
On the other hand, IL-6 and TNF-α levels were de-
creased by CoQ10 application in patients with multiple 
sclerosis [24]. It has been reported that TNF-α level 
reverted with administration of CoQ10 in rats with acute 
pancreatitis [18]. These effects of CoQ10 on cytokines 
can be attributed to its anti-inflammatory properties. 
The anti-inflammatory mechanisms of CoQ10 are ex-
actly unknown [24]. However, CoQ10 have free radical 
scavenging activity and ability to inhibit the activation 
of NF-KB signaling pathway [8]. In addition, it has 
been reported that CoQ10 have antiinflammatory ef-
fects through decrease the release of pro-inflammatory 
cytokines and COX-2 expression during inflammatory 
injury [13].
CoQ10 application to diabetic animals im-
proved the falling in IL-10 level of diabetic group (P 
< 0.05 ; Table 1) in this study. It has been suggested 
that high concentration of glycose causes high pro-
duction of intracellular ROS consequently resulting 
low production anti-inflammatory cytokines and high 
production pro-inflammatory cytokines [2,9,17,28]. 
Thus, the increase IL-10 level with CoQ10 treatment 
in diabetic group may be considered the antioxida-
tive effects of CoQ10. Literature reported that CoQ10 
treatment provoked the expression of IL-10 in ex-
perimental periodontitis rats [10] and that CoQ10 
administration boosted the IL-10 level in rats with 
acute pancreatitis [18]. Our results are in agreement 
with these studies. 
Although the reducing in IL-4 level was al-
leviated by CoQ10 application to diabetic animals 
compared with the diabetic group levels, this change 
was not important. It has been determined that CoQ10 
supplementation didn’t alter IL-4 levels in patient with 
multiple sclerosis [24]. On the other hand, adminis-
tration of CoQ10 in neuropathic pain rats led to the 
decrease in IL-4 level [12]. 
In summary, CoQ10 application for four weeks 
in streptozotocin-induced diabetic rats resulted in 
decreasing levels of pro-inflammatory cytokines and 
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improved levels of anti-inflammatory cytokines. It 
may be due to its antioxidant and anti-inflammatory 
properties, but further studies are needed to elucidate 
the effects of CoQ10 application on inflammation and 
regulation of cytokines. 
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